

PATIENT GROUP DIRECTION (PGD)

**Administration of Adrenaline 1:10,000 (100microgram/ml)
By Registered UHDB Staff providing Advanced Life Support within
Adult UHDB services**

Documentation details

Reference no:	UHDB177
Version no:	1
Valid from:	15/06/2022
Review date:	15/12/2024
Expiry date:	14/06/2025

Change history

Version number	Change details	Date
1	Transferred 2019 version to UHDB format and expand practitioner audience to include other sections trained in ALS and operating in the absence of prescribers (no clinical review/change required as 2021 RCUK guidelines are unchanged)	15/02/2022

Glossary

Abbreviation	Definition

1. PGD template development (PGD Working Group)

PGD Working Group Membership (minimum requirement of consultant, pharmacist and a registered professional who can work under a PGD (or manages the staff who do). If this is a review of existing PGD, replace previous names with the individuals involved for this version

Name	Designation
James Hooley	Medicines Safety Officer (Pharmacist) – 2022
David Jones	Resuscitation & Clinical Skills Manager, UHDB – 2021 consulted on practitioner scope
Peter Cull	Consultant, ED & Clinical Tutor for Simulation – 2019 Clinical input – note no further clinical changes required for this version as UKRC unchanged

Where an antimicrobial is included, confirm the name, designation and date of the antimicrobial pharmacist who has reviewed this version

Name of antimicrobial pharmacist	Designation	Date Reviewed
N/A	-	-

2. Organisational authorisations

The PGD is not legally valid until it has had the relevant organisational authorisation.

University Hospitals of Derby & Burton NHS Foundation Trust authorises this PGD for use by the services or providers listed below:

Authorised for use by the following organisation and/or services
<p>All UHDB staff who are trained to provide advanced life support</p> <p>This is a core PGD and <u>can</u> be implemented in all adult services where training and resources have been allocated by senior staff to do so (see policy and limitations below if in doubt).</p>
Limitations to authorisation
<p>See section 3 qualifications.</p>

Organisational Authorisation (legal requirement).			
Role	Name	Sign	Date
Chief Pharmacist / Deputy	D Moore	Signed copy held in Pharmacy	15/06/2022

Additional signatories (required as per legislation and locally agreed policy)			
Role	Name	Sign	Date
Medicines Safety Officer (pharmacist) <i>Clinical Pharmacist from PGD working group</i>	James Hooley	Signed copy held in Pharmacy	06/06/2022
Interim Medical Director / Deputy <i>Doctor</i>	Dr James Crampton	Signed copy held in Pharmacy	25/05/2022
Chief Nurse / Deputy <i>Registered Professional representing users of the PGD</i>	Phil Bolton	Signed copy held in Pharmacy	16/05/2022

Local enquiries regarding the use of this PGD may be directed to UHDB.PGDgovernance@nhs.net

Section 7 provides a registered health professional authorisation sheet. Individual professionals must be authorised by name to work to this PGD.

3. Characteristics of staff

Qualifications and professional registration	<p>RCUK Advanced Life Support Provider or Instructor (in-date certification)</p> <p>All Divisions, Adult Areas, registered professional with current professional registration operating within their usual scope of practice. Must be a profession permitted by current legislation to practice under a patient group direction.</p>
Initial training	<ul style="list-style-type: none"> - RCUK Advanced Life Support Provider or Instructor - Completion of all Essential-to-role training as outlined in the UHDB PGD policy. - Individual has read and understood full content of this PGD and signed authorisation (section 7) - Completion of Medicines Management Drug Assessment - Trust IV competency
Competency assessment	<p>Staff operating under this PGD are encouraged to review their competency using the NICE Competency Framework for health professionals using patient group directions</p> <p>Individuals operating under this PGD are personally responsible for ensuring they remain up to date with the use of all medicines included in the PGD - if any training needs are identified these should be discussed with either the authorising manager (section 7) or the manager within the PGD working group (section 1) so that further training can be provided as required.</p>
Ongoing training and competency	<p>RCUK Advanced Life Support Provider or Instructor</p> <p>Annual Medicines Safety Training (essential to role)</p> <p>Review/repeat initial training above when this PGD is revised</p> <p>Aseptic non-touch Technique (ANTT)</p>
<p><i>The decision to supply any medication rests with the individual registered health professional who must abide by the PGD and any associated organisation policies.</i></p>	

4. Clinical condition or situation to which this PGD applies

Clinical condition or situation to which this PGD applies	<ul style="list-style-type: none"> • Ventricular Fibrillation (VF) or pulseless Ventricular Tachycardia (VT) • Asystole • Pulseless Electrical Activity (PEA)
Criteria for inclusion	<ul style="list-style-type: none"> • Cardiac arrest in patients over 16 years with a clinical presentation as above • Absence of breathing and a pulse and CPR in progress • Where no prescriber/medic is immediately available to direct medication use
Criteria for exclusion	<ul style="list-style-type: none"> • Previous sensitivity or intolerance to the drug or any ingredient • patients under 16 years old • patients with an active Recommended Summary Plan for Emergency Care and Treatment (ReSPECT) form, where CPR is not recommended
Cautions including any relevant action to be taken	<p>Nil prior to use indications/inclusion scenarios above. Do not delay CPR.</p> <p>Adrenaline is inactivated by sodium bicarbonate; ensure the injection is flushed well.</p> <p>Medical supervision is necessary after administration: In the treatment of anaphylaxis and in other patients with a spontaneous circulation, intravenous adrenaline can cause life-threatening hypertension, tachycardia, arrhythmias and myocardial ischaemia.</p> <p>Post-arrest care, monitor cannula sites for ischaemia/ necrosis.</p>
Action to be taken if the patient is excluded	<ul style="list-style-type: none"> • Refer to medical staff or prescriber for review and prescribing of alternative agent if appropriate. • Record reasons for exclusion in patient notes • Advise patient on alternative treatment
Action to be taken if the patient or carer declines treatment	<ul style="list-style-type: none"> • Not applicable in this situation.
Arrangements for referral for medical advice	<p>For anaphylaxis/cardiac arrest, follow your local medical emergency procedures (e.g. 2222 / 3333 / 999 procedures)</p> <p>In other situations, contact the patient's medical team, the on-call team or refer to agreed medical contacts in your core service (e.g. CCOT to intensivists etc).</p>

5. Description of treatment

Name, strength & formulation of drug	Adrenaline 1:10,000 injection (100microgram/ml), 10ml
Legal category	POM
Route / method of administration	Intravenous or Intraosseous
Indicate any off-label use (if relevant)	n/a
Dose and frequency of administration	1mg in 10mls of 1:10,000 presented as a pre-filled syringe or ampoule over 30 seconds repeated every 3 to 5 minutes if necessary. Flush with at least 20ml Sodium Chloride 0.9% injection
Duration of treatment	Continue as above until a prescriber is available or the episode of resuscitation has ceased.
Quantity to be supplied (leave blank if PGD is administration ONLY)	n/a
Storage	Stock must be securely stored according to UHDB medicines policy and in conditions in line with SPC as detailed below: <ul style="list-style-type: none"> • Store in original container to protect from light • Store below 25 degrees Celsius
Drug interactions	<p><i>The following interactions have been identified and should be considered where it is known a patient is on the following medicines:</i></p> <ul style="list-style-type: none"> • Adrenaline is inactivated by sodium bicarbonate; ensure the injection is flushed well. <p>Other interactions should be assessed following return of circulation as may require additional monitoring (e.g. HR, ECG, blood glucose). A detailed list of drug interactions is available in the SPC, which is available from the electronic Medicines Compendium website: www.medicines.org.uk</p>
Identification & management of adverse reactions	<ul style="list-style-type: none"> • Extravasation/ tissue damage risk • Peripheral shutdown affecting SpO2 measurement and potential ischaemia of extremities with prolonged use • Tachycardia. • Potential foetal hypoxia in pregnancy due to vasoconstriction to placenta. • May increase myocardial oxygen requirement during a time of ischaemia however accepted part of ALS. <p>A detailed list of adverse reactions is available in the SPC, which is available from the electronic Medicines Compendium website: www.medicines.org.uk</p>
Management of and reporting procedure for adverse reactions	<ul style="list-style-type: none"> • Healthcare professionals and patients/carers are encouraged to report suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow

	<p>Card reporting scheme on: https://yellowcard.mhra.gov.uk</p> <ul style="list-style-type: none"> Record all adverse drug reactions (ADRs) in the patient's medical record. <p>Serious adverse reactions (moderate harm or above as per NRLS definition) should be reported via trust incident management system (e.g. Datix) to ensure duty of candour and learning from harm during clinical use.</p>
<p>Written information to be given to patient or carer</p>	<p>None routinely given. If patient has questions, consider providing marketing authorisation holder's patient information leaflet (PIL) provided with the product or obtained via www.medicines.org.uk.</p>
<p>Patient advice / follow up treatment</p>	<p>Monitor for sensitivity reactions and report to a healthcare professional if concerned.</p>
<p>Records</p>	<p>For inpatients, the record of administration must be documented in the ePMA system or medicines chart used in your area.</p> <p>For other areas, an ePMA system should be used if in-use in your area as this will ensure all legal criteria are fulfilled and auditable.</p> <p>Otherwise, records can be made in the medical notes or within the patient pathway (e.g. in daycase or triage where a pathway booklet is in use) but must include the legal requirements below.</p> <p>Either the system holding the record, or the healthcare practitioner working under the PGD, must capture/document all of the following:</p> <ul style="list-style-type: none"> name of individual, address, date of birth and GP with whom the individual is registered (if relevant) name of registered health professional name of medication supplied/administered date of supply/administration dose, form and route of supply/administration quantity supplied/administered batch number and expiry date (if applicable e.g. injections and implants) advice given, including advice given if excluded or declines treatment details of any adverse drug reactions and actions taken Confirm whether <u>supplied and/or administered</u> via Patient Group Direction (PGD) <p>Records should be signed and dated (or a password controlled e-records).</p> <p>All records should be clear, legible and contemporaneous.</p> <p>If you are not recording in ePMA (or other electronic system which has ability to generate audit reports) then a record of all individuals receiving treatment under this PGD should also be in the clinical area for audit purposes as per UHDB PGD policy.</p>

6. Key references

Key references	<ul style="list-style-type: none">• <i>Electronic Medicines Compendium</i> http://www.medicines.org.uk/• <i>Electronic BNF</i> https://bnf.nice.org.uk/• <i>NICE Medicines practice guideline “Patient Group Directions”</i> https://www.nice.org.uk/guidance/mpg2• https://medusa.wales.nhs.uk• <i>RCUK. Adult advanced life support guidelines. May 2021. Accessed 15/02/2022</i> Adult advanced life support Guidelines Resuscitation Council UK
-----------------------	---

7. Registered health professional authorisation sheet

PGD Name [version]: Adult Core - Adrenaline 1:10,000 (100microgram/ml) for ALS [v1.0]
PGD ref: UHDB177

Valid from: 15/06/2022

Expiry date: 14/06/2025

Before signing check that the document you have read is published on Koha or is an in-date hard-copy with all necessary authorisations signed in section 2. The Name/Version/Ref of the document you have read **MUST** match this authorisation form.

Registered health professional

By signing this patient group direction you are indicating that

- a) You agree to and understand all content and commit to only work within this framework.
- b) You have completed any core PGD e-Learning or training records on My Learning Passport or within your department.
- c) You meet the staff characteristics and have completed any additional learning/competency outlined in Section 3 of this PGD.

Patient group directions do not remove inherent professional obligations or accountability.

It is the responsibility of each professional to practise only within the bounds of their own competence and professional code of conduct.

I confirm that I have read and understood the content of this Patient Group Direction and that I am willing and competent to work to it within my professional code of conduct.			
Name	Designation	Signature	Date

Authorising manager / Assessor

I confirm that the registered health professionals named above have declared themselves suitably trained and competent to work under this PGD. I give authorisation on behalf of University Hospitals of Derby & Burton NHS Foundation Trust for the above named health care professionals who have signed the PGD to work under it.			
Name	Designation	Signature	Date

Note to authorising manager

Score through unused rows in the list of registered health professionals to prevent additions post managerial authorisation.

This authorisation sheet must be retained by a manager in the clinical department where the PGD is in-use to serve as a record of those registered health professionals authorised to work under this PGD.